EF-hand calcium binding domain 13, abbreviated as EFHD2, is a protein in humans encoded by the EFHD2 gene. This protein belongs to a family characterized by EF-hand motifs, which are helix-loop-helix structural domains capable of binding calcium ions. EFHD2 is composed of two EF-hand motifs followed by a coiled-coil region and a C-terminal SH3 domain-binding motif. These structural features play a critical role in its function as a calcium sensor and mediator of various calcium-dependent signaling pathways.The EF-hand motifs of EFHD2 undergo a conformational change upon calcium binding, which can modulate the protein's interaction with other cellular components and influence signal transduction processes. The calcium-binding activity of EFHD2 is essential for its involvement in the regulation of the actin cytoskeleton, contributing to cell motility, shape, and potentially to the formation of cellular protrusions such as filopodia.
EFHD2 is widely expressed in various tissues and has been implicated in several physiological and pathological processes. One such role is in the immune system, where it is involved in the regulation of B cell function and may influence the immune response. Additionally, EFHD2 has been studied in the context of neurodegenerative diseases, where its overexpression is associated with the formation of amyloid-beta plaques, a hallmark of Alzheimer's disease pathology.Apart from its role in health, alterations in EFHD2 expression and function have been linked to cancer progression and metastasis, suggesting that it may contribute to tumor cell migration and invasion. Due to its involvement in critical cellular processes, EFHD2 continues to be an area of interest for research, providing insights into calcium signaling mechanisms and their implications for disease.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
A calcium channel blocker that inhibits L-type calcium channels, potentially affecting calcium signaling pathways related to EFHD2. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Another L-type calcium channel blocker, altering calcium influx and possibly modulating EFHD2 activity. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Inhibits ryanodine receptors, decreasing intracellular calcium release, which could indirectly affect EFHD2 function. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
Modulates store-operated calcium entry and IP3 receptors, potentially influencing EFHD2 activity through altered calcium signaling. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
A SERCA pump inhibitor, leading to increased cytosolic calcium levels and potentially affecting EFHD2 activity indirectly. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
Modulates ryanodine receptors, affecting calcium release from the sarcoplasmic reticulum, potentially influencing EFHD2. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $61.00 $307.00 | 2 | |
L-type calcium channel blocker, used to alter calcium signaling pathways that could indirectly affect EFHD2. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
Another L-type calcium channel blocker, potentially modulating calcium signaling pathways related to EFHD2. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Promotes calcium release by antagonizing ryanodine receptors, potentially modulating EFHD2 activity. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
Inhibits the SERCA pump, altering calcium homeostasis, with possible indirect effects on EFHD2 function. | ||||||